Vulval Lesion Excision — Cost, Top Hospitals & Success Rates | MyMedicPlus

Vulval lesion excision encompasses a spectrum of surgical procedures designed to remove abnormal tissue from the external female genitalia (vulva). The approach ranges from a minor office procedure under local anaesthesia to extensive radical surgery under general anaesthesia, depending on the nature, size, and depth of the lesion.

The vulva includes the labia majora, labia minora, clitoris, vestibule, and perineum. Lesions arising in this region may be benign, pre-malignant, or malignant, and accurate histological diagnosis guides the extent of surgical resection required. Colposcopy-directed biopsy is the essential first step in any diagnostic workup before surgical planning.

Contemporary management emphasises the principle of conservative excision with clear margins wherever oncologically safe, preserving anatomical structures and minimising psychosexual morbidity. This reflects a paradigm shift from the radical vulvectomies of earlier decades toward individualised, function-preserving surgery.

The International Society for the Study of Vulvovaginal Disease (ISSVD) and the European Society of Gynaecological Oncology (ESGO) provide regularly updated guidelines that form the evidence base for current surgical decision-making. Multidisciplinary team (MDT) discussion involving gynaecological oncology, pathology, and reconstructive surgery is recommended for all complex or invasive lesions.

Patients should understand that excision addresses the local lesion but does not eliminate the underlying aetiological risk factors — notably human papillomavirus (HPV) infection and chronic inflammatory dermatoses — meaning lifelong surveillance is necessary to detect recurrence or new lesions.

Vulvar Intraepithelial Neoplasia (VIN): VIN is classified as usual-type VIN (uVIN, HPV-associated, predominantly in younger women) and differentiated VIN (dVIN, HPV-independent, associated with lichen sclerosus, arising in older women and carrying a higher malignant potential). ISSVD 2015 terminology recognises high-grade squamous intraepithelial lesion (HSIL) as synonymous with uVIN. Without treatment, approximately 5–10% of VIN3 lesions progress to invasive squamous cell carcinoma (SCC). Surgical excision achieves clear margins and provides definitive histological grading.

Lichen Sclerosus with Suspicious Areas: Lichen sclerosus (LS) is a chronic, immune-mediated dermatosis causing white, atrophic plaques, fissuring, and architectural distortion of the vulva. While LS itself is managed medically with high-potency topical corticosteroids, areas of raised, thickened, or ulcerated epithelium (areas suspicious for dVIN or early SCC) require biopsy and excision.

Bartholin Gland Cysts and Abscesses: The Bartholin glands (greater vestibular glands) lie at the 4 and 8 o'clock positions of the vaginal introitus. Duct obstruction produces a cyst; superimposed infection creates an abscess. Treatment options include incision and drainage (I&D), Word catheter placement, marsupialization, or gland excision (Bartholin gland excision), the latter being preferred for recurrent or infected cysts in women over 40 years where malignancy must be excluded.

Vulval Squamous Cell Carcinoma (SCC): Approximately 90% of vulval cancers are SCCs. Surgical excision with wide local excision (WLE) or radical vulvectomy, combined with inguinofemoral lymph node assessment (sentinel node biopsy or inguinofemoral lymphadenectomy), is the standard curative approach for stage I–II disease.

Other Lesions: Melanoma, Paget disease of the vulva, hidradenoma papilliferum, condylomata acuminata resistant to ablative therapy, sebaceous cysts, lipomas, and fibromas may all require excisional management.

Patient selection for vulval excision depends on the histological diagnosis, lesion extent, patient fitness for anaesthesia, and the woman's reproductive and sexual priorities.

Confirmed histological diagnosis: Excision should only proceed after punch or incisional biopsy has established the diagnosis. Multiple biopsies may be needed for heterogeneous lesions. Colposcopy with acetic acid and toluidine blue staining helps identify the most abnormal areas for targeted biopsy.

Fitness for surgery: Vulval excision is generally well-tolerated. Simple excisions under local anaesthesia are suitable for most women. Radical procedures under general anaesthesia require standard preoperative cardiovascular and respiratory assessment. Patients on anticoagulation require bridging management; those with diabetes need perioperative glucose control.

Multifocal versus unifocal disease: Women with multifocal VIN involving more than 30% of the vulval surface may be candidates for skinning vulvectomy with split-thickness skin grafting, or for non-surgical alternatives such as topical imiquimod 5% cream, particularly where preservation of architecture is paramount (e.g., young, sexually active women).

Age and HPV vaccination status: Younger women with uVIN who have completed HPV vaccination (bivalent, quadrivalent, or 9-valent) may have a lower recurrence risk after excision. Women over 60 years with dVIN on a background of lichen sclerosus have the highest risk of malignant progression and require more aggressive surveillance post-excision.

Contraindications: Active pelvic sepsis should be controlled prior to elective excision. In the case of Bartholin abscess, systemic sepsis mandates I&D as the immediate intervention before definitive Bartholin gland excision can be considered electively.

Wide Local Excision (WLE): WLE is the preferred technique for unifocal VIN and early-stage (T1) vulval cancer. The excision margin is planned to achieve at least 5–8 mm of histologically clear tissue around the lesion. A margin of 8 mm in the fresh specimen corresponds approximately to 5 mm after formalin fixation and histological processing. WLE is performed under general or regional anaesthesia, and the defect is closed primarily if possible, or with local flap reconstruction.

Skinning Vulvectomy: Skinning vulvectomy removes the superficial skin of the vulva down to the subcutaneous fat, preserving the underlying structures. It is indicated for extensive or multifocal VIN involving a large surface area. A split-thickness skin graft from the inner thigh is used to resurface the defect. Outcome depends heavily on histological margin adequacy and graft take.

Radical (Modified) Vulvectomy: For invasive vulval cancer, radical excision with a margin of at least 1 cm of normal tissue is recommended. The classical en-bloc butterfly incision technique has largely been replaced by the triple-incision technique (separate groin incisions) to reduce wound breakdown and lymphoedema rates while maintaining oncological equivalence.

Sentinel Lymph Node Biopsy (SLNB): For SCC lesions 2–4 cm confined to the vulva, with clinically node-negative groins, SLNB using a combination of technetium-99m nanocolloid and patent blue dye identifies the first-echelon draining lymph node. The GROINSS-V studies demonstrated that SLNB is safe, with a 3-year groin recurrence rate of 2.3% in node-negative patients, avoiding the morbidity of full inguinofemoral lymphadenectomy in the 70–80% of patients who are node-negative.

Bartholin Gland Excision and Marsupialization: Marsupialization (creating a permanent epithelialised opening) is preferred for primary Bartholin cysts in younger women, preserving gland function. Excision is preferred for recurrent cysts, post-menopausal women, or when adenocarcinoma of the Bartholin gland is suspected.

Laser Ablation and Electrosurgery: CO2 laser ablation is an alternative to excision for superficial VIN, with the advantage of precise depth control and excellent healing. However, it does not provide a specimen for histology, so excisional biopsy must precede ablation to exclude invasive disease.

Oncological control: Surgical excision with clear margins is the most effective means of treating VIN and early vulval SCC. Five-year overall survival rates for stage I vulval cancer treated with WLE and SLNB exceed 90%, comparing favourably with more radical historical approaches.

Histological certainty: Unlike ablative or topical therapies, excision provides a definitive tissue specimen enabling thorough histological assessment including depth of invasion, margin clearance, lymphovascular space invasion (LVSI), and perineural invasion — features that directly inform adjuvant treatment decisions.

Symptom relief: Vulval lesions frequently cause pruritus, pain, dyspareunia, and psychological distress. Excision of symptomatic lesions produces significant improvements in quality of life, with most women reporting complete resolution of vulval symptoms within 4–6 weeks of healing.

Cancer prevention: Treatment of high-grade VIN (VIN3/HSIL) removes the pre-cancerous tissue, reducing — though not eliminating — the lifetime risk of vulval cancer. The absolute risk reduction is greatest in women with dVIN, where untreated lesions have a higher progression rate than uVIN.

Psychological benefit: Diagnosis of a vulval lesion carries significant anxiety. Definitive surgical treatment, combined with clear communication of histological results, allows women to understand their risk, engage in appropriate surveillance, and regain a sense of control over their health.

Function preservation: Modern conservative techniques minimise disruption to clitoral anatomy, introital calibre, and perineal integrity, resulting in low rates of long-term sexual dysfunction compared with older radical approaches.

Wound breakdown and infection: The vulval region has a rich blood supply that facilitates healing but is also subject to chronic moisture, friction, and microbiological colonisation. Wound dehiscence occurs in 10–30% of cases, depending on the size of the defect and closure technique. Most wound breakdowns heal by secondary intention over 4–8 weeks but may require daily dressing changes and outpatient nurse review.

Haemorrhage: Primary haemorrhage during surgery is managed intraoperatively. Reactionary haemorrhage (within 24 hours) and secondary haemorrhage (days 7–14, associated with wound infection) may require return to theatre. Pre-operative correction of coagulopathy and careful haemostasis reduce this risk.

Lymphoedema: Inguinofemoral lymphadenectomy carries a 25–40% risk of chronic lower-limb lymphoedema. SLNB has reduced this risk substantially — the GROINSS-V II trial demonstrated that sentinel node-positive patients treated with chemoradiation (rather than lymphadenectomy) had significantly lower lymphoedema rates with equivalent oncological outcomes.

Altered sensation and sexual function: Excision near the clitoris or involving significant skin removal can impair clitoral sensation and sexual arousal. Introital narrowing after extensive excision may cause dyspareunia. Pre-operative counselling, physiotherapy, and vaginal dilator therapy are integral to optimising sexual rehabilitation.

Psychosexual impact: Surgery on the external genitalia can have profound effects on body image, self-esteem, and intimate relationships. Referral to a clinical psychologist or sexual health counsellor specialising in vulval conditions should be offered routinely.

Recurrence: VIN recurrence after excision is reported in 10–40% of cases at 5 years, particularly when margins are involved or when the underlying aetiological risk factor (HPV infection, lichen sclerosus) is not addressed. Recurrence does not always indicate treatment failure — ongoing surveillance enables early detection and re-treatment.

Immediate postoperative care: Wound care instructions are provided at discharge, typically involving twice-daily washing with warm water, air drying, and application of a prescribed barrier cream or antimicrobial dressing. Topical lignocaine gel applied before voiding reduces dysuria. Sitz baths are generally discouraged in the early postoperative period.

First postoperative review: A wound review appointment at 2 weeks is standard practice to assess healing, remove any sutures, and review definitive histology results. If histological margins are involved, discussion of re-excision or adjuvant treatment occurs at this visit.

Surveillance schedule: Women treated for VIN or vulval cancer require long-term surveillance. A commonly adopted protocol is 3-monthly review for the first 2 years (the period of highest recurrence risk), then 6-monthly to year 5, then annual review thereafter. Each review includes careful visual inspection of the vulva, vagina, and cervix, with biopsy of any suspicious new areas.

Lichen sclerosus management: Women with LS require continued topical corticosteroid therapy (typically clobetasol propionate 0.05%) to control inflammation and reduce malignant transformation risk. Compliance with maintenance therapy is strongly associated with reduced VIN and cancer incidence.

HPV vaccination: Quadrivalent and 9-valent HPV vaccines reduce the incidence of HPV-associated VIN in previously unexposed women. Vaccination may be offered to women up to the age of 45 years with HPV-associated VIN, although the benefit is greatest in those not previously exposed to HPV types 16 and 18.

Psychosexual and pelvic floor follow-up: Referral to specialist pelvic floor physiotherapy and psychosexual counselling services is recommended for women with sexual dysfunction, introital narrowing, or significant psychological distress following surgery.

The cost of vulval lesion excision varies significantly depending on the complexity of the procedure, the country of treatment, hospital accreditation, and whether the surgery is performed in a public or private healthcare setting.

Procedure complexity: A simple Bartholin cyst marsupialization under local anaesthesia as a day-case procedure is considerably less costly than a radical vulvectomy with inguinofemoral lymphadenectomy requiring a 3–5 day inpatient stay and subsequent reconstructive procedures. Wide local excision sits between these extremes, typically requiring a 1–2 day admission.

Country cost comparison: In the United States, vulval excision procedures typically range from USD 5,000 to USD 25,000 depending on extent. In the United Kingdom under private care, costs range from GBP 3,000 to GBP 15,000. In India, Thailand, and Turkey — destinations popular for medical tourism — equivalent procedures are available at 30–60% of Western costs at JCI-accredited centres with internationally trained gynaecological oncologists.

Histopathology and anaesthesia fees: Specialist gynaecological pathology reporting, SLNB radiopharmaceutical costs (technetium-99m), and anaesthesia fees add substantially to surgical costs and should be itemised in any cost estimate. Sentinel node mapping requires nuclear medicine facilities.

Multidisciplinary team fees: For invasive cancer, MDT review, oncological staging investigations (CT of chest/abdomen/pelvis, PET-CT in some cases), and post-operative oncology consultations represent additional costs beyond the surgical episode.

Insurance and pre-authorisation: In many countries, vulval excision for confirmed or suspected malignancy is covered by health insurance. Pre-cancerous VIN management may require pre-authorisation. Patients are advised to obtain a detailed cost estimate and confirm insurance coverage before scheduling elective procedures abroad.

Topical Imiquimod 5% Cream: Imiquimod is an immune response modifier (toll-like receptor 7 agonist) that stimulates local innate and adaptive immunity against HPV-infected epithelium. Multiple randomised controlled trials have demonstrated complete histological regression in 35–58% of women with uVIN treated with imiquimod 3 times weekly for 16–20 weeks. It is a preferred first-line option for multifocal, extensive, or perianal uVIN in younger women where surgery would cause significant morbidity. Side effects include local inflammation, burning, and ulceration, which can be severe and require dose modification.

Topical Cidofovir 1% Gel: Cidofovir is an antiviral agent with activity against HPV that has demonstrated efficacy in small studies and case series of VIN. It is not widely available commercially for this indication but may be compounded for compassionate use in selected cases.

CO2 Laser Ablation: As described above, laser ablation destroys the abnormal epithelium to a controlled depth. It is used for superficial VIN after invasive disease has been excluded by prior excisional biopsy. It offers better cosmetic and functional outcomes than wide excision for extensive lesions but does not provide histological confirmation of adequacy.

Photodynamic Therapy (PDT): PDT using 5-aminolaevulinic acid (5-ALA) or methyl aminolaevulinate (MAL) with red-light activation produces selective cytotoxicity in HPV-infected epithelial cells. Response rates of 40–50% are reported for uVIN. PDT is available in specialist centres and is particularly suited to extensive, multifocal lesions and perianal disease.

Topical Corticosteroids (for Lichen Sclerosus): High-potency topical corticosteroids (clobetasol propionate 0.05%) are the evidence-based first-line treatment for lichen sclerosus. Regular maintenance therapy controls symptoms, improves tissue quality, and may reduce the risk of malignant transformation, obviating the need for excision in the absence of suspicious lesions.

Watch and Wait with Active Surveillance: Low-grade VIN (VIN1, now classified as LSIL) typically regresses spontaneously, particularly in young immunocompetent women, and does not require excision. Close surveillance at 6-monthly intervals with colposcopy is appropriate. Regression rates for LSIL approach 70–80% in this group.